Investigating the effect of magnesium supplementation on cardiorenal syndrome

Investigating the effect of magnesium oxide supplementation on the quality of life of patients with cardiorenal syndrome caused by chronic heart failure with reduced ejection - A single-arm clinical trials

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230723058900N1

Enrollment

Registered

2023-10-19

Start date

2023-11-06

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Heart failure, unspecified

Interventions

Intervention group: Giving 250 mg magnesium oxide supplements by jalinous Pharmaceutical Company for 3 months with a gap of one day between drug doses..

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Outpatients referred to the clinic diagnosed with chronic heart failure (ECO result with EF less than 40%) Patients with renal failure or evidence of renal damage (decrease in GFR below normal for more than 3 months or albuminuria above 30 mg/dl in 24-hour urine) GFR more than 30 mL/min Serum magnesium below 2 mg/dl

Exclusion criteria

Exclusion criteria: Current treatment with hemodialysis or peritoneal dialysis Donated kidney recipient or kidney donor Coronary artery bypass grafting Previous parathyroidectomy Hyperparathyroidism Current treatment with medication or supplements containing magnesium (antacids) Recent history of treatment with medicine or supplements containing magnesium Any condition that interferes with the absorption of magnesium from the digestive system (short bowel syndrome / chronic pancreatitis) Pregnant mothers, mothers during breastfeeding Allergy to the contents of the medicine Patient participation in other intervention trials Hypothyroidism and hyperthyroidism Patients showing features of other primary kidney diseases Urinary tract infection Any fever associated with infection Active malignancies Liver cirrhosis and chronic alcoholism All people who used cigarettes and other tobacco products ESRD and stage five CKD Laxatives and other nephrotoxic drugs

Design outcomes

Primary

Measure	Time frame
Score of patients in the Kansas City Cardiomyopathy Questionnaire (KCCQ12). Timepoint: Completing the questionnaire at the beginning of the trial and 3 months after taking the magnesium oxide supplement. Method of measurement: Kansas City Cardiomyopathy Questionnaire.;Measuring patients' performance in the 6-minute walking test. Timepoint: Measuring patients' performance at the beginning of the trial and 3 months after magnesium oxide supplementation. Method of measurement: 6-minute walking test.	—

Measure

Time frame

Score of patients in the Kansas City Cardiomyopathy Questionnaire (KCCQ12). Timepoint: Completing the questionnaire at the beginning of the trial and 3 months after taking the magnesium oxide supplement. Method of measurement: Kansas City Cardiomyopathy Questionnaire.;Measuring patients' performance in the 6-minute walking test. Timepoint: Measuring patients' performance at the beginning of the trial and 3 months after magnesium oxide supplementation. Method of measurement: 6-minute walking test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Arami

Rasht University of Medical Sciences

samira523@yahoo.com+98 13 3361 8177

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026